(RTTNews) - ResMed Inc.(RMD), announced Thursday that its NightOwl home sleep apnea test or HSAT is now available across the United States, providing a simple and effective at-home diagnostic solution for obstructive sleep apnea or OSA.
NightOwl is a disposable HSAT device that records up to 10 nights of sleep data for a single patient, capturing night-to-night variability and providing clinicians with a comprehensive view of an individual's sleep patterns.
The company stated that NightOwl is an FDA-cleared test designed to offer healthcare providers and patients a more convenient and accurate method for diagnosing OSA from home.
The device features a small, disposable fingertip sensor that records up to 10 nights of sleep data, which is then analyzed via a cloud-based platform for rapid physician review.
With 80% of OSA cases remaining undiagnosed, ResMed aims to improve accessibility and detection rates.
The NightOwl system integrates auto-scored results, pairs with ResMed's myAir app, and is fully disposable, eliminating the need for device returns or reprocessing.
Currently, RMD is trading at $212.98 down by 4.52 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
